MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.72 and traded as high as $2.08. MediciNova shares last traded at $1.99, with a volume of 31,933 shares trading hands.
Analyst Ratings Changes
MNOV has been the topic of a number of research reports. D. Boral Capital started coverage on shares of MediciNova in a report on Monday, December 2nd. They issued a "buy" rating and a $9.00 price target on the stock. StockNews.com started coverage on shares of MediciNova in a report on Friday. They issued a "hold" rating on the stock.
View Our Latest Research Report on MediciNova
MediciNova Price Performance
The company has a market cap of $96.13 million, a PE ratio of -9.33 and a beta of 0.84. The stock's 50-day moving average is $2.03 and its 200 day moving average is $1.73.
Hedge Funds Weigh In On MediciNova
An institutional investor recently raised its position in MediciNova stock. Geode Capital Management LLC lifted its holdings in MediciNova, Inc. (NASDAQ:MNOV - Free Report) by 10.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 505,966 shares of the biopharmaceutical company's stock after buying an additional 47,201 shares during the period. Geode Capital Management LLC owned approximately 1.03% of MediciNova worth $1,063,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 9.90% of the company's stock.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
